The Next Wave of Obesity Drugs - Opportunities and risk
-
GLP-1 weight loss drugs Wegovy
(semaglutide) and Zepbound (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023, due to their unprecedented weight-loss efficacyThe next waves might not be as colossal, but they still hold potential for investors navigating these waters.
Læs hele blogindlægget fra Tommy Carstensen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind